Lung cancer is one of the deadliest diseases in the world, the main cause of cancer-related deaths. Now, scientists from research institutions in the United States claim they have succeeded in developing a tool with artificial intelligence (AI) that can accurately predict the risk of developing the disease, aiding prevention and early treatment.
With the collaboration of American researchers from the Mass General Cancer Center (Massachusetts General Hospital) and the Massachusetts Institute of Technology (MIT), the AI-powered Sybil tool, which can predict lung cancer risk, has been developed. do not smoke and have no history of lung disease.
Currently, low-dose radiation computed tomography of the thorax (LDCT) is the main test recommended to detect lung cancer in people aged 50 to 80 years who smoke. That’s why Sybil was developed to analyze TCBD scans using artificial intelligence to track information that can determine how long it will take for the disease to develop in a patient – it describes a period of one to six years.
Lung cancer and AI
“Sybil can look at an image and predict a patient’s risk of developing lung cancer within six years. I’m excited by the translation efforts led by the Massachusetts General Hospital team that aim to change outcomes in patients who would otherwise develop it.” advanced disease,” said Regina Barzilay, one of the study’s authors and Jameel Clinic (MIT) faculty leader.
According to Florian Fintelmann, one of the study’s authors, Sybil only requires the analysis of a TCBD review to understand the problem and thus help monitor the disease in humans. Artificial intelligence was evaluated using three independent datasets by examining different people who smoked or never smoked.
In these three sets, Sybil was able to accurately predict patients’ lung cancer, but the researchers point out that more work is needed on the subject. Further studies are also needed to understand whether Sybil would work correctly among all people, as 92% of the people in the study were white.
The results of the study were published in an article published in the scientific journal Journal of Clinical Oncology.
Source: Tec Mundo
I am Bret Jackson, a professional journalist and author for Gadget Onus, where I specialize in writing about the gaming industry. With over 6 years of experience in my field, I have built up an extensive portfolio that ranges from reviews to interviews with top figures within the industry. My work has been featured on various news sites, providing readers with insightful analysis regarding the current state of gaming culture.
